View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 28, 2020

Italy gives approval to trial osteoporosis drug for Covid-19 treatment

The Italian Medicines Agency (AIFA) has granted approval to conduct human clinical trials on raloxifene, a generic osteoporosis drug to treat paucisymptomatic Covid-19 patients.

The Italian Medicines Agency (AIFA) has granted approval to conduct human clinical trials on raloxifene, a generic osteoporosis drug to treat paucisymptomatic Covid-19 patients.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

According to researchers, the hormone therapy, which imitates the effects of estrogen to increase bone density, could potentially reduce the symptoms and make patients less contagious.

Researchers identified the drug’s potential to treat Covid-19 using supercomputers to screen over 400,000 molecules for chemical characteristics that can prevent the virus, reported Reuters.

Promoted by the Exscalate4Cov public-private consortium and submitted to AIFA by Dompé farmaceutici as coordinator of the E4C project, the Covid-19 clinical trial is taking place at the National Institute for Infectious Diseases ‘L Spallanzani’ in Italy, which is leading the study.

Raloxifene could also block replication of the virus in cells, slowing down disease progression.

The news agency quoted Dompé Farmaceutici research head Marco Allegretti as saying: “It inhibits virus replication, thus preventing the worsening of patients with mild symptoms, and also decreases infectivity, limiting the viral load.”

The Phase I trial will enrol 450 hospital and home patients. They will randomly receive raloxifene oral capsules or placebo for seven days.

It may enrol 174 more patients in the final stage, with the enrolment expected to last 12 weeks.

The European Commission and coordinates supercomputing centres in Italy, Germany and Spain with pharmaceutical companies and research centres funded the Excalate4Cov platform.

It processes digital models of the coronavirus’ protein and matches them against a database of thousands of existing drugs.

Furthermore, the platform uses a chemical library of 500 billion molecules and can process three million molecules per second using four supercomputers of more than 122 Petaflops.

By March, Italy had become the most affected country of Covid-19 in Europe, with deaths surpassing China.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology